V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
Clinical trial NCT03486834 · COMPLETED
Trial details
- NCT number
- NCT03486834
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-30
- Primary completion
- 2020-10-30
- Enrollment
- 2200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.